CDER Director Proposes Reclassification of Opioid Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CDER Director Proposes Reclassification of Opioid Products


Janet Woodcock, MD, director of FDA’s Center for Drug Evaluation and Research (CDER) has issued a statement that FDA plans on submitting formal recommendations for the reclassification of hydrocodone combination products into Schedule II. FDA has been evaluating the appropriate use of opioid analgesic drug products after years of concern about the misuse of such products.

The US Department of Health and Human Services (HHS) was asked by the US Drug Enforcement Administration in 2009 to provide recommendations for the possible change for hydrocodone combination products from Schedule III to Schedule II to increase the control of the products. In response, CDER plans to submit recommendations by early December to reclassify opioid analgesic drugs into Schedule II.

“Due to the unique history of this issue and the tremendous amount of public interest, we are announcing the agency’s intent to recommend to HHS that hydrocodone combination products should be reclassified to a different and more restrictive schedule,” states Woodcock. “This determination comes after a thorough and careful analysis of extensive scientific literature, review of hundreds of public comments on the issue, and several public meetings, during which we received input from a wide range of stakeholders, including patients, health care providers, outside experts, and other government entities.”

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here